Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Conatus Pharmaceutic (CNAT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,428
  • Shares Outstanding, K 30,262
  • Annual Sales, $ 35,380 K
  • Annual Income, $ -17,400 K
  • 36-Month Beta 3.41
  • Price/Sales 1.76
  • Price/Cash Flow N/A
  • Price/Book 3.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.14
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.25
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.69 +20.71%
on 01/25/19
2.56 -20.31%
on 01/29/19
+0.22 (+12.09%)
since 01/15/19
3-Month
1.15 +77.39%
on 12/24/18
4.94 -58.70%
on 11/26/18
-2.62 (-56.22%)
since 11/15/18
52-Week
1.15 +77.39%
on 12/24/18
7.95 -74.34%
on 03/09/18
-3.14 (-60.62%)
since 02/15/18

Most Recent Stories

More News
Conatus (CNAT) Completes Enrollment in Phase II NASH Study

Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.

CNAT : 2.04 (+0.49%)
GALT : 5.12 (+3.02%)
NVS : 89.88 (+0.97%)
PFE : 42.40 (+1.02%)
Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company's first-in-class, orally-active pan-caspase...

CNAT : 2.04 (+0.49%)
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?

On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.

MGNX : 21.84 (+3.41%)
CNAT : 2.04 (+0.49%)
GWPH : 150.49 (-0.53%)
NSTG : 23.31 (-0.26%)
Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company's completed Phase 2 clinical trials.

CNAT : 2.04 (+0.49%)
Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.

CNAT : 2.04 (+0.49%)
BVX : 6.48 (+1.09%)
NVS : 89.88 (+0.97%)
PFE : 42.40 (+1.02%)
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

CNAT : 2.04 (+0.49%)
IONS : 58.98 (+0.19%)
EXEL : 22.26 (-0.18%)
GILD : 67.59 (+1.84%)
BIIB : 332.87 (+2.51%)
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

A low key week for the biotech sector with focus on regular pipeline updates.

CNAT : 2.04 (+0.49%)
IONS : 58.98 (+0.19%)
EXEL : 22.26 (-0.18%)
GILD : 67.59 (+1.84%)
BIIB : 332.87 (+2.51%)
Implied Volatility Surging for Conatus (CNAT) Stock Options

Investors need to pay close attention to Conatus (CNAT) stock based on the movements in the options market lately.

CNAT : 2.04 (+0.49%)
Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.

CNAT : 2.04 (+0.49%)
BVX : 6.48 (+1.09%)
NVS : 89.88 (+0.97%)
PFE : 42.40 (+1.02%)
Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis

NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at...

CNAT : 2.04 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade CNAT with:

Business Summary

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of...

See More

Key Turning Points

2nd Resistance Point 2.11
1st Resistance Point 2.07
Last Price 2.04
1st Support Level 2.00
2nd Support Level 1.97

See More

52-Week High 7.95
Fibonacci 61.8% 5.35
Fibonacci 50% 4.55
Fibonacci 38.2% 3.75
Last Price 2.04
52-Week Low 1.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar